Policyholder Services

Am I covered to inject Kybella for the treatment of double chins?

Updated 5/29/2018

Coverage for this procedure is included under OMIC’s Surgery Class 1 rating classification.

Kybella (formerly known as ATX-101) is an injectable drug made from deoxycholic acid.  In April 2015, the FDA approved Kybella as a treatment for adults with moderate to severe fat below the chin. The safety and effectiveness of Kybella for treatment of submental fat were established in two large clinical trials. Use of Kybella for the treatment of fat outside of the submental area is neither approved nor recommended by the FDA.



Please refer to OMIC's Copyright and Disclaimer regarding the contents on this website

Leave a comment

Six reasons OMIC is the best choice for ophthalmologists in America.

Best at defending claims.

An ophthalmologist pays nearly half a million dollars in premiums over the course of a career. Premium paid is directly related to a carrier’s claims experience. OMIC has a higher win rate taking tough cases to trial, full consent to settle (no hammer) clause, and access to the best experts. OMIC pays 25% less per claim than other carriers. As a result, OMIC has consistently maintained lower base rates than multispecialty carriers in the U.S.